Cited 9 times in
Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2016-02-19T11:07:10Z | - |
dc.date.available | 2016-02-19T11:07:10Z | - |
dc.date.issued | 2001 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/142439 | - |
dc.description.abstract | We investigated the dose-related effect of the 5-fluorouracil (5-FU)/leucovorin regimen on survival in 139 colon cancer patients with Dukes’ B2 and C2 stage disease. Chemotherapy consisted of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin injected daily for 5 days in every 4 weeks for a maximum of 12 cycles. The total dose of 5-FU administered per body surface area had a significant effect on the 5-year disease-free survival and 5-year overall survival in stage B2 and C2 colon cancer patients (P=0.0018, P=0.0011). Analysis with reference to the median DSDI demonstrated that there was a significant difference in 5-year survival in Dukes’ C2 (P=0.0016), but survival was not affected by the dose intensity. Multivariate analysis demonstrated that only the total dose of 5-FU administered per surface area affected the 5-year disease-free survival and 5-year overall survival (P=0.0016, P=0.0007, respectively). It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 215~224 | - |
dc.relation.isPartOf | CANCER LETTERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Colonic Neoplasms/drug therapy* | - |
dc.subject.MESH | Colonic Neoplasms/mortality | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/adverse effects | - |
dc.subject.MESH | Fluorouracil/therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Leucovorin/adverse effects | - |
dc.subject.MESH | Leucovorin/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Survival Analysis | - |
dc.title | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer | - |
dc.type | Article | - |
dc.contributor.college | Researcher Institutes (부설 연구소) | - |
dc.contributor.department | Cancer Metastasis Research Center (암전이연구센터) | - |
dc.contributor.googleauthor | Joong B Ahn | - |
dc.contributor.googleauthor | Kwang Y Shim | - |
dc.contributor.googleauthor | Hei C Jeung | - |
dc.contributor.googleauthor | Sun Y Rha | - |
dc.contributor.googleauthor | Nae C Yoo | - |
dc.contributor.googleauthor | Nam K Kim | - |
dc.contributor.googleauthor | Jae K Roh | - |
dc.contributor.googleauthor | Jin S Min | - |
dc.contributor.googleauthor | Byung S Kim | - |
dc.contributor.googleauthor | Hyun C Chung | - |
dc.identifier.doi | 10.1016/S0304-3835(01)00485-2 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J00448 | - |
dc.identifier.eissn | 1872-7980 | - |
dc.identifier.pmid | 11369143 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0304383501004852 | - |
dc.subject.keyword | 5-Fluorouracil | - |
dc.subject.keyword | Total dose | - |
dc.subject.keyword | Adjuvant chemotherapy | - |
dc.subject.keyword | Colon cancer | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 167 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 215 | - |
dc.citation.endPage | 224 | - |
dc.identifier.bibliographicCitation | CANCER LETTERS, Vol.167(2) : 215-224, 2001 | - |
dc.identifier.rimsid | 31003 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.